Overview

A Study of OV101 in Individuals With Fragile X Syndrome

Status:
Completed
Trial end date:
2020-02-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability and efficacy of oral OV101 (gaboxadol) in subjects with Fragile X syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
Ovid Therapeutics Inc.
Treatments:
Gaboxadol